Recombinant Human PPARg Protein，His

PPARγ (Peroxisome Proliferator-Activated Receptor Gamma) is a crucial member of the nuclear receptor superfamily, playing a significant role in regulating glucose and lipid metabolism, as well as adipogenesis. Discovered in the late 1990s, PPARγ was initially identified as a key factor in fat cell differentiation. Its important role in metabolic diseases, particularly insulin resistance and type 2 diabetes, spurred extensive research. Activation of PPARγ by various ligands, including thiazolidinediones (TZDs), has shown promise in enhancing insulin sensitivity, making it a target for therapeutic intervention in metabolic disorders. However, the use of TZDs has been linked to adverse effects, such as weight gain and fluid retention, highlighting the need for a deeper understanding of PPARγ function and regulation. Recent advances in recombinant protein technology have enabled the production of PPARγ in substantial quantities, facilitating detailed biochemical and structural studies. Research into the binding interactions of PPARγ with its ligands and co-regulators is essential for the development of novel therapeutic agents that can selectively modulate its activity, potentially minimizing side effects while maximizing metabolic benefits. This growing body of knowledge not only contributes to our understanding of PPARγ's role in metabolism but also opens new avenues for targeted drug design and the treatment of related metabolic conditions.